There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments.
Corcept Therapeutics (CORT)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company’s shares closed last Tuesday at $20.31.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
Corcept Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.67, implying a 50.8% upside from current levels. In a report issued on February 2, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Stealth Biotherapeutics (MITO)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Stealth Biotherapeutics today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.65, close to its 52-week low of $0.61.
According to TipRanks.com, Chen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stealth Biotherapeutics with a $4.00 average price target.
Cerevel Therapeutics Holdings (CERE)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Cerevel Therapeutics Holdings today and set a price target of $50.00. The company’s shares closed last Tuesday at $30.10.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of
Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Strong Buy with an average price target of $42.33, implying a 40.7% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CORT:
- Needham Thinks Crispr Therapeutics AG’s Stock is Going to Recover
- SolarEdge Technologies (SEDG) Gets a Buy Rating from Needham
- Toast Posts Greater-than-Expected Q4 Loss; Shares Decline Over 15%
- Needham Maintains a Buy Rating on Green Thumb Industries (GTBIF)
- Pacira Pharmaceuticals (PCRX) Gets a Buy Rating from Needham
